At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 48 target
Drug / intervention
inetetamab +1 moredrug
Likely dose
inetetamab 8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Clinical Study Evaluating the Safety and Efficacy of Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Patients With Advanced Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating inetetamab and Pytotinib for Non-small Cell Lung Cancer. Targeting 48 participants across 1 site.
Detailed Summary
This is a Phase 1, open-label study to evaluate the safety and the efficacy of inetetamab in combination with pyrotinib in patients in HER2 mutant or amplified patients with advanced non-small cell lung cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20222023202420252026
Enrollment StartJul 2021
First PostedAug 2021
Primary CompletionAug 2023
Study CompletionFeb 2025
TodayJul 2026
First PostedAug 23, 2021
Enrollment StartJul 28, 2021
Primary CompletionAug 1, 2023
Study CompletionFeb 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 4.9 years ago
Interventions
inetetamabdrug
All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
Pytotinibdrug
Starting pytotinib Dose of 240mg: Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w.